Soleus Capital Management L.P. Lowers Holdings in MDxHealth SA (NASDAQ:MDXH)

Soleus Capital Management L.P. cut its holdings in MDxHealth SA (NASDAQ:MDXH - Free Report) by 22.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 851,688 shares of the company's stock after selling 253,312 shares during the quarter. Soleus Capital Management L.P. owned approximately 1.80% of MDxHealth worth $2,019,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. FAS Wealth Partners Inc. grew its position in shares of MDxHealth by 49.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock valued at $58,000 after purchasing an additional 8,100 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock valued at $47,000 after purchasing an additional 10,000 shares during the last quarter. Geode Capital Management LLC acquired a new stake in shares of MDxHealth during the fourth quarter valued at $25,000. XTX Topco Ltd purchased a new stake in MDxHealth during the 4th quarter worth about $63,000. Finally, Northern Right Capital Management L.P. purchased a new stake in MDxHealth during the 4th quarter worth about $246,000.

MDxHealth Price Performance

MDxHealth stock traded down $0.02 during midday trading on Friday, reaching $2.04. 60,462 shares of the company were exchanged, compared to its average volume of 86,155. The company has a market capitalization of $96.47 million, a price-to-earnings ratio of -1.34 and a beta of 1.32. The firm's 50-day simple moving average is $1.67 and its 200-day simple moving average is $1.85. MDxHealth SA has a 1 year low of $1.35 and a 1 year high of $3.50. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.06). The company had revenue of $24.29 million for the quarter, compared to analysts' expectations of $22.62 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. On average, analysts anticipate that MDxHealth SA will post -1.15 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded MDxHealth to a "hold" rating in a research report on Saturday.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.